000			03029cam a2200337 a 4500
003			EG-GiCUC
005			20250223031958.0
008			180418s2017 ua dh f m 000 0 eng d
040			_aEG-GiCUC _beng _cEG-GiCUC
041	0		_aeng
049			_aDeposite
097			_aM.Sc
099			_aCai01.08.09.M.Sc.2017.Ne.M
100	0		_aNesma Ahmed Abdelrahman Mohamed Shiha
245	1	0	_aModulatory effect of certain drugs on diabetic cardiovascular complications in rats / _cNesma Ahmed Abdelrahman Mohamed Shiha ; Supervised Amina Salem Attia , Lamiaa Ahmed Ahmed
246	1	5	_aتعديل تأثير أدوية معينة فى المضاعفات القلبية الوعائية لمرض السكر فى الجرذان
260			_aCairo : _bNesma Ahmed Abdelrahman Mohamed Shiha , _c2017
300			_a221 P. : _bcharts , facsimiles ; _c25cm
502			_aThesis (M.Sc.) - Cairo University - Faculty of Pharmacy - Department of Pharmacology and Toxicology
520			_aThe current study aimed to investigate the possible beneficial effects of saxagliptin and escitalopram each alone or in combination on metabolic changes and cardiac complications in type 2 diabetic rats. Diabetes was induced by feeding the rats HFFD for 8 weeks followed by a subdiabetogenic dose of STZ (35 mg/kg, i.p.). Treatment with saxagliptin (10 mg/kg; p.o.) and escitalopram (10 mg/kg; p.o.) alone or in combination was continued for 4 weeks. At the end of the experiment, blood samples were collected for determination of serum parameters (glucose, insulin, fructosamine, HOMA-IR, TGs and TC). Animals were then euthanized and heart samples were collected for biochemical determinations (RAGE, NADPH oxidase, TAC, NF-mB, TNF-Ü, TGF-Ý1, caspase-8, p53, Ü-MHC, Ý-MHC and connexin-43) as well as histopathological examination. The HFFD/STZ model resulted in disturbances in both glycemic and lipid profiles along with an increase in BW. The model also induced myocardial damage that was evident by the increased oxidative stress, inflammation, fibrosis, apoptosis and hypertrophy as well as reduced conduction and contractility. Both saxagliptin and escitalopram alleviated the HFFD/STZ-induced metabolic and cardiac derangements. Combining both drugs promoted additional decreases in serum insulin, fructosamine and TC levels. Moreover, the combined regimen provided further improvement in controlling the diabetic-induced oxidative stress, inflammation, fibrosis, hypertrophy and contractility dysfunction which could be related to the reduction in RAGE content. Escitalopram thus could be considered a favorable antidepressant option in diabetic patients
530			_aIssued also as CD
653		4	_aCardiovascular complications
653		4	_aDiabetes mellitus
653		4	_aDiabetic cardiomyopathy
700	0		_aAmina Salem Attia , _eSupervisor
700	0		_aLamiaa Ahmed Ahmed , _eSupervisor
856			_uhttp://172.23.153.220/th.pdf
905			_aNazla _eRevisor
905			_aShimaa _eCataloger
942			_2ddc _cTH
999			_c65934 _d65934